Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{fb7e98010b5d41f98a84f6e840a72c99,
title = "Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression",
abstract = "Current pharmacological treatments for depression have a significant treatment-onset-response delay, an insufficient efficacy for many patients and fail to reverse cognitive dysfunction. Erythropoietin (EPO) has neuroprotective and neurotrophic actions and improves cognitive function in animal models of acute and chronic neurodegenerative conditions and in patients with cognitive decline.",
keywords = "Affect, Animals, Controlled Clinical Trials as Topic, Depression, Erythropoietin, Humans, Memory Disorders, Mood Disorders",
author = "Miskowiak, {Kamilla W} and Maj Vinberg and Harmer, {Catherine J} and Hannelore Ehrenreich and Kessing, {Lars V}",
year = "2012",
doi = "10.1007/s00213-011-2511-1",
language = "English",
volume = "219",
pages = "687--98",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer",
number = "3",

}

RIS

TY - JOUR

T1 - Erythropoietin

T2 - a candidate treatment for mood symptoms and memory dysfunction in depression

AU - Miskowiak, Kamilla W

AU - Vinberg, Maj

AU - Harmer, Catherine J

AU - Ehrenreich, Hannelore

AU - Kessing, Lars V

PY - 2012

Y1 - 2012

N2 - Current pharmacological treatments for depression have a significant treatment-onset-response delay, an insufficient efficacy for many patients and fail to reverse cognitive dysfunction. Erythropoietin (EPO) has neuroprotective and neurotrophic actions and improves cognitive function in animal models of acute and chronic neurodegenerative conditions and in patients with cognitive decline.

AB - Current pharmacological treatments for depression have a significant treatment-onset-response delay, an insufficient efficacy for many patients and fail to reverse cognitive dysfunction. Erythropoietin (EPO) has neuroprotective and neurotrophic actions and improves cognitive function in animal models of acute and chronic neurodegenerative conditions and in patients with cognitive decline.

KW - Affect

KW - Animals

KW - Controlled Clinical Trials as Topic

KW - Depression

KW - Erythropoietin

KW - Humans

KW - Memory Disorders

KW - Mood Disorders

U2 - 10.1007/s00213-011-2511-1

DO - 10.1007/s00213-011-2511-1

M3 - Journal article

VL - 219

SP - 687

EP - 698

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 3

ER -

ID: 36475096